Justin Ferdinandus1, Elisabeth Eppard1, Florian C Gaertner1, Stefan Kürpig1, Rolf Fimmers2, Anna Yordanova1, Stefan Hauser3, Georg Feldmann4, Markus Essler1, Hojjat Ahmadzadehfar5. 1. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. 2. Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany. 3. Department of Urology, University Hospital Bonn, Bonn, Germany; and. 4. Department of Internal Medicine, MED III, University Hospital Bonn, Bonn, Germany. 5. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany hojjat.ahmadzadehfar@ukb.uni-bonn.de.
Abstract
Radioligand therapy (RLT) with 177Lu-PSMA-617 (PSMA is prostate-specific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we evaluated the effect of different pretherapeutic parameters on the therapeutic response measured by prostate-specific antigen (PSA) 2 mo after RLT. METHODS: RLT was performed in 40 hormone-refractory patients with distant metastases and progressive disease (mean age, 71.4 y). 68Ga-PSMA-11 PET/CT was performed in all patients 1-2 wk before RLT. All patients were treated with a mean of 6 GBq. The SUVmax of tumor lesions was determined using region-of-interest analysis. Complete blood counts, renal and liver function assessments, previous therapies, pain medication, and SUVs were included in the analysis. PSA was assessed 2 mo after RLT. RESULTS: In the univariate analysis, younger age, higher levels of γ-glutamyl transferase, lower pretherapeutic hemoglobin, a higher Gleason score, a higher number of platelets, higher C-reactive protein, regular need for pain medication, and higher lactate dehydrogenase had a negative impact on the therapeutic response; however, the multivariate analysis revealed that the most significant independent factors were the number of platelets and regular need for pain medication. The response was independent of the amount of PSMA uptake as well as previous therapies and other measured factors. CONCLUSION: A PSA decline of more than 50% was observed significantly more in patients without a regular need for analgesics.
Radioligand therapy (RLT) with 177Lu-PSMA-617 (PSMA is prostate-specific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we evaluated the effect of different pretherapeutic parameters on the therapeutic response measured by prostate-specific antigen (PSA) 2 mo after RLT. METHODS: RLT was performed in 40 hormone-refractory patients with distant metastases and progressive disease (mean age, 71.4 y). 68Ga-PSMA-11 PET/CT was performed in all patients 1-2 wk before RLT. All patients were treated with a mean of 6 GBq. The SUVmax of tumor lesions was determined using region-of-interest analysis. Complete blood counts, renal and liver function assessments, previous therapies, pain medication, and SUVs were included in the analysis. PSA was assessed 2 mo after RLT. RESULTS: In the univariate analysis, younger age, higher levels of γ-glutamyl transferase, lower pretherapeutic hemoglobin, a higher Gleason score, a higher number of platelets, higher C-reactive protein, regular need for pain medication, and higher lactate dehydrogenase had a negative impact on the therapeutic response; however, the multivariate analysis revealed that the most significant independent factors were the number of platelets and regular need for pain medication. The response was independent of the amount of PSMA uptake as well as previous therapies and other measured factors. CONCLUSION: A PSA decline of more than 50% was observed significantly more in patients without a regular need for analgesics.
Authors: H Ahmadzadehfar; P Albers; A Bockisch; M Boegemann; C Böhme; W Burchert; M Dietlein; A Drzezga; U Fabry; G Feldmann; A Heidenreich; A Heinzel; K Herrmann; A Heyll; C Höhling; C Kreuzer; D Laufer; R Mengel; F M Mottaghy; H-W Müller; S C Müller; E Ost; K Rahbar; W Reifenhäuser; M Schäfers; C Schlenkhoff; M Schmidt; I Schmidt-Wolf; C Wildenhain; B Zimmer; M Essler Journal: Urologe A Date: 2018-06 Impact factor: 0.639
Authors: Hojjat Ahmadzadehfar; Simone Wegen; Anna Yordanova; Rolf Fimmers; Stefan Kürpig; Elisabeth Eppard; Xiao Wei; Carl Schlenkhoff; Stefan Hauser; Markus Essler Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-09 Impact factor: 9.236
Authors: Anna Yordanova; Anja Becker; Elisabeth Eppard; Stefan Kürpig; Christian Fisang; Georg Feldmann; Markus Essler; Hojjat Ahmadzadehfar Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-23 Impact factor: 9.236
Authors: Christian Daniel Fankhauser; Cédric Poyet; Stephanie G C Kroeze; Benedikt Kranzbühler; Helena I Garcia Schüler; Matthias Guckenberger; Philipp A Kaufmann; Thomas Hermanns; Irene A Burger Journal: World J Urol Date: 2018-07-20 Impact factor: 4.226
Authors: Mohammad S Sadaghiani; Sara Sheikhbahaei; Rudolf A Werner; Kenneth J Pienta; Martin G Pomper; Lilja B Solnes; Michael A Gorin; Nae-Yuh Wang; Steven P Rowe Journal: Eur Urol Date: 2021-04-08 Impact factor: 20.096
Authors: Hojjat Ahmadzadehfar; Stephan Schlolaut; Rolf Fimmers; Anna Yordanova; Stefan Hirzebruch; Carl Schlenkhoff; Florian C Gaertner; Zool Hilmi Awang; Stefan Hauser; Markus Essler Journal: Oncotarget Date: 2017-10-07
Authors: Sazan Rasul; Tim Wollenweber; Lucia Zisser; Elisabeth Kretschmer-Chott; Bernhard Grubmüller; Gero Kramer; Shahrokh F Shariat; Harald Eidherr; Markus Mitterhauser; Chrysoula Vraka; Werner Langsteger; Marcus Hacker; Alexander R Haug Journal: Cancers (Basel) Date: 2021-05-20 Impact factor: 6.639
Authors: Hojjat Ahmadzadehfar; Stefanie Zimbelmann; Anna Yordanova; Rolf Fimmers; Stefan Kürpig; Elisabeth Eppard; Florian C Gaertner; Xiao Wei; Stefan Hauser; Markus Essler Journal: Oncotarget Date: 2017-02-25